Dermata Therapeutics Financials

DRMAW Stock  USD 0.02  0  12.50%   
Based on the key indicators related to Dermata Therapeutics' liquidity, profitability, solvency, and operating efficiency, Dermata Therapeutics Warrant is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Dermata Therapeutics' Total Current Liabilities is fairly stable compared to the past year. Total Stockholder Equity is likely to climb to about 7.7 M in 2025, whereas Other Current Liabilities is likely to drop slightly above 620.1 K in 2025. Key indicators impacting Dermata Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.434.42
Significantly Down
Slightly volatile
Investors should never underestimate Dermata Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Dermata Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Dermata Therapeutics Warrant.

Net Income

(7.37 Million)

-3.43M-7.95M-9.61M-7.79M-7.02M-7.37M100%
  
Understanding current and past Dermata Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Dermata Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Dermata Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Dermata Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dermata Therapeutics Warrant. Check Dermata Therapeutics' Beneish M Score to see the likelihood of Dermata Therapeutics' management manipulating its earnings.

Dermata Therapeutics Stock Summary

Dermata Therapeutics competes with Dermata Therapeutics. Dermata Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP249845116
LocationCalifornia; U.S.A
Business Address3525 Del Mar
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.dermatarx.com
Phone858 800 2543
CurrencyUSD - US Dollar

Dermata Therapeutics Key Financial Ratios

Dermata Therapeutics Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets605.5K11.6M6.9M8.0M9.2M6.4M
Other Current Liab133.5K1.0M425.9K757.6K871.2K620.1K
Net Debt3.0M(10.8M)(6.2M)(7.4M)(6.7M)(7.0M)
Retained Earnings(28.1M)(36.0M)(45.6M)(53.4M)(48.0M)(50.5M)
Accounts Payable104.3K515.2K496.7K866.0K995.9K510.3K
Cash530.4K10.8M6.2M7.4M8.6M5.9M
Other Current Assets75.1K825.1K690.6K532.1K612.0K483.3K
Total Liab3.8M1.5M922.6K1.6M1.5M1.6M
Net Invested Capital367.7K10.1M6.0M6.4M7.3M5.3M
Total Current Assets605.5K11.6M6.9M8.0M9.2M6.4M
Net Working Capital(3.2M)10.1M6.0M6.4M7.3M4.3M

Dermata Therapeutics Key Income Statement Accounts

The reason investors look at the income statement is to determine what Dermata Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Net Interest Income(197.3K)(45.6K)63.6K203.4K234.0K245.7K
Depreciation And Amortization322.014.1K9.7K8.0M9.2M9.7M
Selling General Administrative1.6M4.4M4.0M4.0M4.6M3.5M
Other Operating Expenses3.2M7.9M9.7M8.0M9.2M7.3M
Operating Income(3.2M)(7.9M)(9.7M)(8.0M)(7.2M)(7.6M)
Net Income From Continuing Ops(3.2M)(7.9M)(9.6M)(7.3M)(6.6M)(6.9M)
Ebit(3.2M)(7.9M)(9.7M)(7.8M)(7.0M)(7.4M)
Research Development1.6M3.5M5.7M4.1M4.7M3.8M
Ebitda(3.2M)(7.8M)(9.7M)247.2K284.3K298.5K
Total Operating Expenses3.2M7.9M9.7M8.0M9.2M7.3M
Income Before Tax(3.2M)(7.9M)(9.6M)(7.8M)(7.0M)(7.4M)
Total Other Income Expense Net(63.7K)(45.6K)63.6K247.2K284.3K298.5K
Net Income(3.4M)(7.9M)(9.6M)(7.8M)(7.0M)(7.4M)
Income Tax Expense197.3K45.6K(9.7K)(8.0K)(7.2K)(6.9K)

Dermata Therapeutics Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash(1.5M)10.3M(4.6M)1.2M1.1M1.0M
Stock Based Compensation0.01.9M930.3K522.1K600.4K738.9K
Free Cash Flow(4.0M)(5.7M)(8.8M)(6.4M)(5.8M)(6.1M)
Change In Working Capital(755.8K)289.6K(153.6K)863.7K993.2K1.0M
Begin Period Cash Flow2.0M530.4K10.8M6.2M7.2M4.6M
Other Cashflows From Financing Activities3.2M(430K)287.0187.0168.3159.89
Other Non Cash Items(36.5K)14.1K930.3K522.1K600.4K506.6K
Total Cash From Operating Activities(4.0M)(5.7M)(8.8M)(6.4M)(5.8M)(6.1M)
Issuance Of Capital Stock268.8K16.0M4.3M5.7M6.5M6.9M
Net Income(3.2M)(7.9M)(9.6M)(7.8M)(7.0M)(7.4M)
Total Cash From Financing Activities2.6M16.0M4.3M7.6M8.7M7.7M
End Period Cash Flow530.4K10.8M6.2M7.4M8.6M5.9M

Dermata Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Dermata Therapeutics's current stock value. Our valuation model uses many indicators to compare Dermata Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dermata Therapeutics competition to find correlations between indicators driving Dermata Therapeutics's intrinsic value. More Info.
JavaScript chart by amCharts 3.21.15KTTAWDRMAEFTRWZIVOWDRMAW -1.5-1.0-0.50 -45-40-35-30-25-20-15-10-50
Dermata Therapeutics Warrant is rated # 3 in return on equity category among its peers. It is rated # 4 in return on asset category among its peers . At this time, Dermata Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Dermata Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Dermata Therapeutics Systematic Risk

Dermata Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Dermata Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Dermata Therapeutics correlated with the market. If Beta is less than 0 Dermata Therapeutics generally moves in the opposite direction as compared to the market. If Dermata Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Dermata Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Dermata Therapeutics is generally in the same direction as the market. If Beta > 1 Dermata Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
JavaScript chart by amCharts 3.21.15Nov2025Mar2025Feb0.0100.0150.0200.0250.030 10K20K30K40K -0.003-0.002-1m01m0.0020.003 43.5K44K44.5K Show all
JavaScript chart by amCharts 3.21.15Dermata Therapeutics Volume Dermata Therapeutics Closing Prices Dow Jones Industrial Closing Prices - Benchmark Dermata Therapeutics Beta

Steps to analyze company Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Dermata Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Dermata has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Dermata Therapeutics' financials are consistent with your investment objective using the following steps:
  • Review Dermata Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Dermata Therapeutics' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Dermata Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Dermata Therapeutics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Dermata Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dermata Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Dermata Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.001319)

-0.001319
At this time, Dermata Therapeutics' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Dermata Therapeutics March 4, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Dermata Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Dermata Therapeutics Warrant. We use our internally-developed statistical techniques to arrive at the intrinsic value of Dermata Therapeutics Warrant based on widely used predictive technical indicators. In general, we focus on analyzing Dermata Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Dermata Therapeutics's daily price indicators and compare them against related drivers.

Additional Tools for Dermata Stock Analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.